Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2024

Open Access 01-12-2024 | Osteosarcoma | Research

High expression of SRSF1 facilitates osteosarcoma progression and unveils its potential mechanisms

Authors: Shuqi Li, Xinyi Huang, Shuang Zheng, Wenhui Zhang, Fang Liu, Qinghua Cao

Published in: BMC Cancer | Issue 1/2024

Login to get access

Abstract

Background

SRSF1, a member of Serine/Arginine-Rich Splicing Factors (SRSFs), has been observed to significantly influence cancer progression. However, the precise role of SRSF1 in osteosarcoma (OS) remains unclear. This study aims to investigate the functions of SRSF1 and its underlying mechanism in OS.

Methods

SRSF1 expression level in OS was evaluated on the TCGA dataset, TAGET-OS database. qRT-PCR and Western blotting were employed to assess SRSF1 expression in human OS cell lines as well as the interfered ectopic expression states. The effect of SRSF1 on cell migration, invasion, proliferation, and apoptosis of OS cells were measured by transwell assay and flow cytometry. RNA sequence and bioinformatic analyses were conducted to elucidate the targeted genes, relevant biological pathways, and alternative splicing (AS) events regulated by SRSF1.

Results

SRSF1 expression was consistently upregulated in both OS samples and OS cell lines. Diminishing SRSF1 resulted in reduced proliferation, migration, and invasion and increased apoptosis in OS cells while overexpressing SRSF1 led to enhanced growth, migration, invasion, and decreased apoptosis. Mechanistically, Gene Ontology (GO) analysis, Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis, and Gene Set Enrichment Analysis (GSEA) revealed that the biological functions of SRSF1 were closely associated with the dysregulation of the protein targeting processes, location of the cytosolic ribosome, extracellular matrix (ECM), and proteinaceous extracellular matrix, along with the PI3K-AKT pathway, Wnt pathway, and HIPPO pathway. Transcriptome analysis identified AS events modulated by SRSF1, especially (Skipped Exon) SE events and (Mutually exclusive Exons) MXE events, revealing potential roles of targeted molecules in mRNA surveillance, RNA degradation, and RNA transport during OS development. qRT-PCR confirmed that SRSF1 knockdown resulted in the occurrence of alternative splicing of SRRM2, DMKN, and SCAT1 in OS.

Conclusions

Our results highlight the oncogenic role of high SRSF1 expression in promoting OS progression, and further explore the potential mechanisms of action. The significant involvement of SRSF1 in OS development suggests its potential utility as a therapeutic target in OS.
Appendix
Available only for authorised users
Literature
1.
Yang C et al. Bone microenvironment and Osteosarcoma Metastasis. Int J Mol Sci, 2020. 21(19).
2.
Corre I et al. The Osteosarcoma Microenvironment: a Complex but Targetable Ecosystem. Cells, 2020. 9(4).
3.
Chen Y, et al. Advances in targeted therapy for osteosarcoma based on molecular classification. Pharmacol Res. 2021;169:105684.PubMedCrossRef
4.
Shoaib Z, Fan TM, Irudayaraj JMK. Osteosarcoma mechanobiology and therapeutic targets. Br J Pharmacol. 2022;179(2):201–17.PubMedCrossRef
5.
Kager L, Tamamyan G, Bielack S. Novel insights and therapeutic interventions for pediatric osteosarcoma. Future Oncol (London England). 2017;13(4):357–68.CrossRef
6.
Zhang Y, et al. Alternative splicing and cancer: a systematic review. Signal Transduct Target Therapy. 2021;6(1):78.CrossRef
7.
Sciarrillo R, et al. The role of alternative splicing in cancer: from oncogenesis to drug resistance. Drug Resist Updates: Reviews Commentaries Antimicrob Anticancer Chemother. 2020;53:100728.CrossRef
8.
9.
Wan L, Deng M, Zhang H. SR Splicing Factors Promote Cancer via Multiple Regul Mech Genes, 2022. 13(9).
10.
11.
12.
Du J-X, et al. Splicing factor SRSF1 promotes breast cancer progression via oncogenic splice switching of PTPMT1. J Experimental Clin Cancer Research: CR. 2021;40(1):171.PubMedCentralCrossRef
13.
Khan M, et al. Sequence-dependent recruitment of SRSF1 and SRSF7 to intronless lncRNA NKILA promotes nuclear export via the TREX/TAP pathway. Nucleic Acids Res. 2021;49(11):6420–36.PubMedPubMedCentralCrossRef
14.
Shen L, et al. Skipping of exon 10 in Axl pre-mRNA regulated by PTBP1 mediates invasion and metastasis process of liver cancer cells. Theranostics. 2020;10(13):5719–35.PubMedPubMedCentralCrossRef
15.
Sun J, et al. The long non-coding RNA PFI protects against pulmonary fibrosis by interacting with splicing regulator SRSF1. Cell Death Differ. 2021;28(10):2916–30.PubMedPubMedCentralCrossRef
16.
Lv Y, et al. SRSF1 inhibits autophagy through regulating Bcl-x splicing and interacting with PIK3C3 in lung cancer. Signal Transduct Target Therapy. 2021;6(1):108.CrossRef
17.
Qu G, et al. LncRNA WWOXAS1 inhibits the proliferation, migration and invasion of osteosarcoma cells. Mol Med Rep. 2018;18(1):779–88.PubMedPubMedCentral
18.
Duan G, et al. Knockdown of MALAT1 inhibits osteosarcoma progression via regulating the miR34a/cyclin D1 axis. Int J Oncol. 2019;54(1):17–28.PubMed
19.
20.
Jin H et al. Long noncoding RNA H19 regulates LASP1 expression in osteosarcoma by competitively binding to miR29a3p Oncol Rep, 2021. 46(3).
21.
22.
Marasco LE, Kornblihtt AR. The physiology of alternative splicing. Nat Rev Mol Cell Biol. 2023;24(4):242–54.PubMedCrossRef
23.
Wan L et al. Splicing Factor SRSF1 Promotes Pancreatitis and KRASG12D-Mediated Pancreatic Cancer Cancer Discovery, 2023.
24.
25.
Kim Y, et al. METTL3 regulates alternative splicing of cell cycle-related genes via crosstalk between mRNA m6A modifications and splicing factors. Am J Cancer Res. 2023;13(4):1443–56.PubMedPubMedCentral
26.
Zhang Y, et al. Oncogenic lncRNA ZNFX1 antisense RNA 1 promotes osteosarcoma cells proliferation and metastasis by stabilizing serine and arginine–rich splicing factor 3. Bioengineered. 2022;13(3):5962–74.PubMedPubMedCentralCrossRef
27.
28.
de Miguel FJ, et al. Identification of alternative splicing events regulated by the oncogenic factor SRSF1 in lung cancer. Cancer Res. 2014;74(4):1105–15.PubMedCrossRef
29.
30.
Anczuków O, et al. The splicing factor SRSF1 regulates apoptosis and proliferation to promote mammary epithelial cell transformation. Nat Struct Mol Biol. 2012;19(2):220–8.PubMedPubMedCentralCrossRef
31.
Lee H, et al. Diagnostic utility of transcriptome sequencing for rare mendelian diseases Genetics. Medicine: Official J Am Coll Med Genet. 2020;22(3):490–9.
32.
Karamanos NK, et al. Extracellular matrix-based cancer targeting. Trends Mol Med. 2021;27(10):1000–13.PubMedCrossRef
33.
Insua-Rodríguez J, Oskarsson T. The extracellular matrix in breast cancer. Adv Drug Deliv Rev. 2016;97:41–55.PubMedCrossRef
34.
Parker AL, et al. Extracellular matrix profiles determine risk and prognosis of the squamous cell carcinoma subtype of non-small cell lung carcinoma. Genome Med. 2022;14(1):126.PubMedPubMedCentralCrossRef
35.
Zhang T, et al. Cancer-associated fibroblasts-derived HAPLN1 promotes tumour invasion through extracellular matrix remodeling in gastric cancer. Gastric Cancer: Official J Int Gastric Cancer Association Japanese Gastric Cancer Association. 2022;25(2):346–59.CrossRef
36.
Cui J, et al. The role of extracelluar matrix in osteosarcoma progression and metastasis. J Experimental Clin Cancer Research: CR. 2020;39(1):178.PubMedCentralCrossRef
37.
Dzamukova M, et al. Mechanical forces couple bone matrix mineralization with inhibition of angiogenesis to limit adolescent bone growth. Nat Commun. 2022;13(1):3059.PubMedPubMedCentralCrossRef
38.
Muñoz Ú, et al. Hepatocyte growth factor enhances alternative splicing of the Kruppel-like factor 6 (KLF6) tumor suppressor to promote growth through SRSF1. Mol Cancer Research: MCR. 2012;10(9):1216–27.PubMedCrossRef
39.
Fu Y, et al. SRSF1 and SRSF9 RNA binding proteins promote wnt signalling-mediated tumorigenesis by enhancing β-catenin biosynthesis. EMBO Mol Med. 2013;5(5):737–50.PubMedPubMedCentralCrossRef
40.
Rajendran D, et al. Regulation of numb isoform expression by activated ERK signaling. Oncogene. 2016;35(39):5202–13.PubMedCrossRef
41.
Li H, et al. ZIP10 drives osteosarcoma proliferation and chemoresistance through ITGA10-mediated activation of the PI3K/AKT pathway. J Experimental Clin Cancer Research: CR. 2021;40(1):340.PubMedCentralCrossRef
42.
Yang B, et al. Circular RNA circ_001422 promotes the progression and metastasis of osteosarcoma via the miR-195-5p/FGF2/PI3K/Akt axis. J Experimental Clin Cancer Research: CR. 2021;40(1):235.PubMedCentralCrossRef
43.
Lv D, et al. M6A demethylase FTO-mediated downregulation of DACT1 mRNA stability promotes wnt signaling to facilitate osteosarcoma progression. Oncogene. 2022;41(12):1727–41.PubMedCrossRef
44.
45.
Yi Y et al. Niclosamide and Pyrvinium Are Both Potential Therapeutics for Osteosarcoma, Inhibiting Wnt-Axin2-Snail Cascade Cancers, 2021. 13(18).
46.
Li Y, Yang S, Yang S. Verteporfin inhibits the progression of spontaneous Osteosarcoma caused by Trp53 and Rb1 Deficiency in Ctsk-Expressing cells via Impeding Hippo Pathway. Cells, 2022. 11(8).
47.
Luo Y, et al. Mir-624-5p promoted tumorigenesis and metastasis by suppressing hippo signaling through targeting PTPRB in osteosarcoma cells. J Experimental Clin Cancer Research: CR. 2019;38(1):488.PubMedCentralCrossRef
48.
Bonnal SC, López-Oreja I, Valcárcel J. Roles and mechanisms of alternative splicing in cancer - implications for care. Nat Rev Clin Oncol. 2020;17(8):457–74.PubMedCrossRef
49.
50.
51.
Zhang W, Zhang S, Wang Z. Prognostic value of 12 m7G methylation-related miRNA markers and their correlation with immune infiltration in breast cancer. Front Oncol. 2022;12:929363.PubMedPubMedCentralCrossRef
52.
Dong W, et al. Glioma glycolipid metabolism: MSI2-SNORD12B-FIP1L1-ZBTB4 feedback loop as a potential treatment target. Clin Translational Med. 2021;11(5):e411.CrossRef
53.
Yang LF, Yang F, Zhang FL, Xie YF, Hu ZX, Huang SL, Shao ZM, Li DQ. Discrete functional and mechanistic roles of chromodomain Y-like 2 (CDYL2) transcript variants in breast cancer growth and metastasis. Theranostics. 2020;10(12):5242–58.PubMedPubMedCentralCrossRef
54.
Shah RB et al. FANCI functions as a repair/apoptosis switch in response to DNA crosslinks. Dev Cell, 2021. 56(15).
55.
Ju Z, Xiang J, Xiao L, He Y, Zhang L, Wang Y, Lei R, Nie Y, Yang L, Miszczyk J, Zhou P, Huang R. TXNL4B regulates radioresistance by controlling the PRP3-mediated alternative splicing of FANCI. MedComm (2020). 2023;4(3):e258.
56.
Fu RH, Liu SP, Huang SJ, Chen HJ, Chen PR, Lin YH, Ho YC, Chang WL, Tsai CH, Shyu WC, Lin SZ. Aberrant alternative splicing events in Parkinson’s disease. Cell Transpl. 2013;22(4):653–61.CrossRef
57.
Shehadeh LA, Yu K, Wang L, Guevara A, Singer C, Vance J, Papapetropoulos S. SRRM2, a potential blood biomarker revealing high alternative splicing in Parkinson’s disease. PLoS ONE. 2010;5(2):e9104.PubMedPubMedCentralCrossRef
58.
Tomsic J, et al. A germline mutation in SRRM2, a splicing factor gene, is implicated in papillary thyroid carcinoma predisposition. Sci Rep. 2015;5:10566.PubMedPubMedCentralCrossRef
59.
60.
Huang C, et al. Dermokine contributes to epithelial-mesenchymal transition through increased activation of signal transducer and activator of transcription 3 in pancreatic cancer. Cancer Sci. 2017;108(11):2130–41.PubMedPubMedCentralCrossRef
61.
Zhang Y, et al. Overexpression of Dermokine-α enhances the proliferation and epithelial-mesenchymal transition of pancreatic tumor cells. Cell Signal. 2022;99:110439.PubMedCrossRef
62.
Lang X, Huang C, Cui H. Prognosis Analysis and Validation of Fatty Acid Metabolism-Related lncRNAs and Tumor Immune Microenvironment in Cervical Cancer. J Immunol Res. 2022; 2022:4954457.
63.
Zeng C, Liu Y, He R, Lu X, Dai Y, Qi G, Liu J, Deng J, Lu W, Jin J, Liu Q. Identification and validation of a novel cellular senescence-related lncRNA prognostic signature for predicting immunotherapy response in stomach adenocarcinoma. Front Genet. 2022;13:935056.PubMedPubMedCentralCrossRef
Metadata
Title
High expression of SRSF1 facilitates osteosarcoma progression and unveils its potential mechanisms
Authors
Shuqi Li
Xinyi Huang
Shuang Zheng
Wenhui Zhang
Fang Liu
Qinghua Cao
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-024-12346-y

Other articles of this Issue 1/2024

BMC Cancer 1/2024 Go to the issue

Research

All-trans-retinoic acid modulates glycolysis via H19 and telomerase: the role of mir-let-7a in estrogen receptor-positive breast cancer cells

Research

Paclitaxel liposome (Lipusu) based chemotherapy combined with immunotherapy for advanced non-small cell lung cancer: a multicenter, retrospective real-world study

Research

Exosomes derived from cancer-associated fibroblasts promote tumorigenesis, metastasis and chemoresistance of colorectal cancer by upregulating circ_0067557 to target Lin28

Research

Biplex quantitative PCR to detect transcriptionally active human papillomavirus 16 from patient saliva

Research

Attitudes towards risk-stratified breast cancer screening: a population-based survey among 5,001 Danish women

Research

Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myeloma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits